News
Merck expects $200M tariff hit amid Gardasil fallout
The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results beat estimates. First quarter sales were $15.5 billion, above the $15.3 billion analysts had predicted. Adjusted earnings of $2.22 per share outpaced expectations of $2.13 a share.
Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion, as the ...
Local drugmakers donated $4 million to President Donald Trump’s inauguration committee earlier this year as the administration contemplates tariffs that could impose major financial strain on the ...
Announcing better-than-expected financials for Q1 2025 on Thursday, Merck (NYSE:MRK) lowered its full-year outlook for earnings to account for various headwinds, including a $200M impact related ...
Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...
Merck cut its 2025 adjusted earnings projection to a range between $8.82 and $8.97 a share from a previous estimate of $8.88 to $9.03 a share. The new guidance includes a charge of roughly $200 ...
Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement may come as soon as Monday, the people said, asking not to be ...
Merck & Co. cut its 2025 earnings outlook, partly to account for recently imposed tariffs that it projects will total $200 million. The projection comes in light of the tariffs implemented so ...
Drugmaker's stock gains as quarterly profit and sales extend a long string of beats and full-year outlook is kept intact Shares of Merck & Co. were headed higher in early Thursday trading ...
On a per-share basis, the Rahway, New Jersey-based company said it had profit of $2.01. Earnings, adjusted for one-time gains and costs, came to $2.22 per share. The results exceeded Wall Street ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback